Abstract:BackgroundTislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, demonstrated clinical activity and was well tolerated in patients with previously treated advanced HCC in the open-label, multicenter, Phase 2 RATIONALE-208 study (NCT03419897). We report exploratory analysis of the association of gene expression profiles (GEPs) with response to tislelizumab in patients with previously treated advanced HCC.MethodsEligible patients who had received ≥1 prior line of systemic therapy for advanced HCC received tislelizumab (200 mg) intravenously once every 3 weeks and tumor response was evaluated per RECIST v.1.1. Baseline tumor sampling was optional and GEP analysis was performed using HTG EdgeSeq Precision Immuno-Oncology panel in 138 tumor samples (fresh tumor, n=6; archival tumor, n=132). Signature scores were calculated using Gene Set Variation Analysis package with publicly available gene signatures (GS). GS or genes differentially expressed between responders and non-responders (NRs) were determined using Wilcoxon rank-sum test and modified t-test with limma. Distributions of overall survival (OS) and progression-free survival (PFS) for GS subgroups (high vs low) were estimated by Kaplan-Meier method. Hierarchical clustering of NRs was achieved using 1-Pearson’s correlation and average linkage. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.Results249 patients were enrolled and received ≥1 dose of tislelizumab; 138 patients had evaluable GEP data, of which 132 patients had evaluable GEP and tumor response data. GEP analysis demonstrated that CD4 T cell, CD8 T cell, cytotoxic T lymphocyte and major histocompatibility complex class I signatures were enriched in responders, and cancer-associated fibroblasts, angiogenesis and hypoxia signatures were enriched in NRs (figure 1). CD8B_PDCD1_9, a novel GS identified, comprises 9 genes highly expressed in responders: CD8B, CXCL13, KLRD1, NKG7, HLA-A, HLA-G, LAG3, PDCD1 and KREMEN1. Higher objective response rate (ORR; p<0.0001, by Fisher’s exact test) and longer PFS (p=0.005, by log rank test) were observed in patients with high vs low CD8B_PDCD1_9 score (ORR: 26% vs 3%; median PFS: 2.8 months vs 1.8 months). To explore the heterogeneity of molecular features in NRs, NRs were clustered into 3 subgroups using a series of tumor-immune GS. OS and PFS for the 3 NR subgroups with distinct GS are summarized in table 1.Abstact 360 Figure 1Correlation between GS and ORR in patients with previously treated advanced HCC treated with tislelizumab monotherapyAbstact 360 Table 1OS and PFS of NR subgroupsCl, confidence interval; NE, not evaluable; GS, gene signature; NR, non-responder; OS, overall survival; PFS, progression-free survivalConclusionsThis exploratory analysis identified distinct GS associated with tumor response and resistance to tislelizumab monotherapy in patients with previously treated advanced HCC and increases our understanding of the tumor microenvironment. Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by a safety monitoring committee.

A real-world evaluation of tislelizumab in patients with head and neck cancer

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Tislelizumab For The Treatment Of Classical Hodgkin'S Lymphoma

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Long-term Pooled Safety Analysis of Tislelizumab As Monotherapy or in Combination with Chemotherapy in Patients with Advanced Cancers.

360 Tumor-immune Signatures Associated with Response or Resistance to Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

[Tislelizumab monotherapy for the treatment of recurrent/metastatic head and neck squamous cell carcinoma].

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers

P-19 Subgroup Analysis of the Number of Prior Lines of Systemic Therapy and Clinical Outcomes Associated with Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

1264P Updated Analysis of Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study